October 2017

The Life Sciences Industry of Tomorrow: Healthy Canadians, Healthy Future - OTTAWA

11:30am-1:30pm | Fairmont Chateau Laurier - 1 Rideau Street, Ottawa

What is the true contribution of the innovative pharmaceutical industry to the Canadian economy and R&D investment? What are the potential impacts of federal policy changes aimed at lowering drug prices? Is there a middle ground where Canada is able to lower prices while still retaining its position as a top tier destination for clinical trials and the launch of new innovative medicines? IMC President Pamela Fralick and panelists will discuss the results of a Fall 2017 analysis by EY about industry’s contributions to Canada and how industry and government can work together to enhance affordable, equitable and timely access to new therapies.

- Lunch will be served -

Member price:
Individual seat: $89 +HST
Table (seats 10): $800 +HST

Regular price:
Individual seat: $110 +HST
Table (seats 10): $990 +HST

- For information about accessibility, please email lapointe@economicclub.ca
- Dietary restriction notes and meal requests must be submitted to dickinson@economicclub.ca by Thursday, October 26, 2017

*The views expressed on the Economic Club platform are not that of the Economic Club or its affiliates but of the speakers alone and the organizations they represent*

The Life Sciences Industry of Tomorrow: Healthy Canadians, Healthy Future - OTTAWA

Connie Côté

Health Charities Coalition of Canada

Connie Côté

Connie Côté has been involved in the not-for-profit, regulatory and charitable health sector for over twenty years and is currently the Chief Executive Officer of the Health Charities Coalition of Canada (HCCC). Her priorities at HCCC include advocating on issues related to health research and health policy and working with members to identify areas of alignment and opportunity.

Prior to joining HCCC, Connie worked with the Canadian Lung Association where she held various management positions, including leading the National Lung Health Framework. Previously, she worked for the Federation of Medical Regulatory Authorities of Canada and the Royal College of Physicians and Surgeons of Canada.

Connie enjoys working within multi-disciplinary teams, navigating change and building strong partnerships.

Connie lives in Ottawa with her two children.

Dr. Bill Cameron

Senior Scientist, Division of Infectious Diseases and Respirology
Medical Director, Clinical Research, Ottawa Hospital Research Institute

Dr. Bill Cameron

Dr. Bill Cameron is Medical Director for Clinical Research at the Ottawa Hospital Research Institute, Senior Scientist for the Clinical Epidemiology Program at the Ottawa Hospital Research Institute, Professor for the Faculty of Medicine at The University of Ottawa, and physician for the Division of Infectious Diseases at The Ottawa Hospital. He has practiced general infectious disease medicine at The Ottawa Hospital for the last 29 years. In the past twenty years or more, Dr. Cameron’s work has made substantial impact in HIV epidemiology and therapeutics.


Ed Dybka

President and CEO
AstraZeneca Canada Inc.

Ed Dybka

Ed Dybka is the President of AstraZeneca Canada Inc., part of AstraZeneca PLC, one of the world’s leading biopharmaceutical companies.

Mr. Dybka has worked in the Canadian pharmaceutical industry for close to 30 years and has led AstraZeneca Canada Inc since 2015. In 2012, he led the Canadian establishment of Almirall, a start-up biopharmaceutical company focused on the treatment of respiratory diseases and affiliated with Almirall S.A., with headquarters in Barcelona, Spain.

Prior to establishing Almirall in Canada, Mr. Dybka held a number of executive roles at GlaxoSmithKline Canada from 2004 to 2012, including Vice President of Marketing, Sales and Public Affairs & Reimbursement. During this time, he was accountable for the marketing and sales of all GSK pharmaceutical products, including specialty care, oncology and vaccines, achieving strong commercial performance and employee engagement. Earlier in his career, Mr. Dybka held progressively senior roles in product management and product development, as well as sales, at Glaxo Wellcome Canada Inc. and Zeneca Pharma Inc.

Mr. Dybka is currently a Co-Chair of Life Sciences Ontario, an organization that represents and promotes the province's vibrant and diverse life sciences sector. He is also the Chair of the Acute Coronary Treatment (ACT) Foundation and is a Director of Innovative Medicines Canada. He has served on a number of other Boards, including the George Hull Centre for Children and Families, the Pharmaceutical Advertising and Advisory Board, the Canadian Pharmaceutical Distribution Network, and The Mississauga Board of Trade.

Mr. Dybka holds a Bachelor of Science degree in Toxicology from the University of Toronto. He lives in Toronto with his wife and two children.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca’s Canadian headquarters are located in Mississauga, Ontario. For more information, please visit the company’s website at www.astrazeneca.ca.

Pamela Fralick

Innovative Medicines Canada

Pamela Fralick

Driven by a life-long commitment to improving Canadians’ health and well-being, Pamela works with the country’s research-based pharmaceutical companies to ensure that all Canadians have access to the medicines they need, when they need them, and that Canada remains an attractive place to invest in the life sciences. Her unique perspective on the policy issues of the day is informed by her decades of working closely with patients and researchers to find solutions to some of our most pressing healthcare challenges.
Prior to IMC, Pamela was President and CEO of the Canadian Cancer Society, where she led the transformation of the organization’s operational and governance structures, helping to strengthen its position as the country’s leading cancer-fighting charity.
Her patient-centric perspective is also shaped by past leadership roles at the Canadian Healthcare Association (now HealthCareCAN), the Canadian Physiotherapy Association, the Health Action Lobby (HEAL), the Health Charities Coalition of Canada (HCCC), CAMH (Centre for Addiction and Mental Health) and the Canadian Centre on Substance Abuse.

Our Sponsors

Telus Interac Green Shield Canada